NovaBay Pharmaceuticals (NBY) Short term Debt (2019 - 2025)
Historic Short term Debt for NovaBay Pharmaceuticals (NBY) over the last 8 years, with Q3 2025 value amounting to $149000.0.
- NovaBay Pharmaceuticals' Short term Debt rose 19215.69% to $149000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $149000.0, marking a year-over-year increase of 19215.69%. This contributed to the annual value of $65000.0 for FY2024, which is 9428.32% down from last year.
- Latest data reveals that NovaBay Pharmaceuticals reported Short term Debt of $149000.0 as of Q3 2025, which was up 19215.69% from $111000.0 recorded in Q2 2025.
- NovaBay Pharmaceuticals' 5-year Short term Debt high stood at $1.3 million for Q3 2023, and its period low was $51000.0 during Q3 2024.
- In the last 4 years, NovaBay Pharmaceuticals' Short term Debt had a median value of $149000.0 in 2025 and averaged $525909.1.
- Per our database at Business Quant, NovaBay Pharmaceuticals' Short term Debt plummeted by 9598.43% in 2024 and then soared by 19215.69% in 2025.
- Quarter analysis of 4 years shows NovaBay Pharmaceuticals' Short term Debt stood at $105000.0 in 2021, then skyrocketed by 982.86% to $1.1 million in 2023, then plummeted by 94.28% to $65000.0 in 2024, then skyrocketed by 129.23% to $149000.0 in 2025.
- Its last three reported values are $149000.0 in Q3 2025, $111000.0 for Q2 2025, and $84000.0 during Q1 2025.